Skip to main content
. 2016 Oct 15;18(Suppl 5):v1–v75. doi: 10.1093/neuonc/now207

Table 24.

One-, Two-, Five-. and Ten-Year Relative Survival Ratesa,b for Selected Malignant Brain and Other Central Nervous System Tumors by Age Groups, SEER 18 Registries, 2000-2013c

Age Group (years) 1-Year 2-Year 5-Year 10-Year
Histology N d % 95% CI % 95% CI % 95% CI % 95% CI
Pilocytic astrocytoma 0-19 2,627 98.8 (98.2-99.1) 98.4 (97.8-98.8) 96.7 (95.8-97.4) 95.8 (94.6-96.7)
20-44 723 96.6 (95.0-97.8) 94.9 (92.9-96.3) 91.8 (89.2-93.8) 85.6 (81.6-88.8)
45-54 136 95.8 (90.2-98.2) 86.1 (78.3-91.2) 78.5 (69.1-85.3) 75.1 (64.7-82.8)
55-64 84 97.1 (88.0-99.3) 90.8 (80.4-95.9) 82.3 (70.0-89.9) 74.6 (57.6-85.5)
65-74 -- -- -- -- -- -- -- -- --
75+ -- -- -- -- -- -- -- -- --
Diffuse astrocytoma 0-19 856 93.2 (91.3-94.7) 87.6 (85.1-89.7) 83.9 (81.0-86.3) 82.1 (78.9-84.8)
20-44 2,067 93.1 (91.9-94.2) 86.7 (85.1-88.2) 67.8 (65.5-70.0) 49.5 (46.6-52.4)
45-54 938 76.9 (73.9-79.5) 62.1 (58.8-65.3) 44.1 (40.5-47.6) 32.0 (27.9-36.1)
55-64 812 57.1 (53.6-60.6) 37.4 (33.8-40.9) 22.3 (19.1-25.8) 14.6 (11.1-18.7)
65-74 600 42.0 (37.9-46.1) 26.4 (22.7-30.2) 15.0 (11.7-18.6) 10.5 (7.1-14.5)
75+ 508 24.9 (21.0-28.9) 12.5 (9.5-16.0) 6.7 (4.1-10.1) -- --
Anaplastic astrocytoma 0-19 292 67.5 (61.7-72.7) 41.4 (35.4-47.4) 28.3 (22.6-34.3) 19.3 (13.6-25.9)
20-44 1,250 88.9 (87.0-90.6) 74.7 (72.0-77.2) 54.4 (51.1-57.6) 39.6 (35.8-43.3)
45-54 675 73.4 (69.8-76.7) 50.7 (46.6-54.7) 31.5 (27.4-35.6) 22.6 (18.1-27.3)
55-64 678 53.7 (49.8-57.5) 30.0 (26.3-33.8) 13.5 (10.6-16.9) 6.6 (3.8-10.4)
65-74 518 38.2 (33.8-42.5) 18.7 (15.2-22.5) 8.2 (5.6-11.5) 4.8 (2.6-8.0)
75+ 378 18.9 (15.0-23.3) 8.9 (6.0-12.5) -- -- -- --
Glioblastoma 0-19 444 59.0 (54.1-63.5) 33.3 (28.6-38.0) 16.8 (13.0-21.1) 12.5 (8.7-17.1)
20-44 2,852 69.7 (67.9-71.4) 40.4 (38.5-42.3) 19.1 (17.4-20.7) 10.9 (9.4-12.5)
45-54 5,524 56.8 (55.4-58.1) 25.2 (24.0-26.4) 7.6 (6.7-8.4) 3.8 (3.1-4.7)
55-64 8,531 45.6 (44.5-46.7) 17.6 (16.7-18.5) 4.6 (4.1-5.2) 2.0 (1.5-2.6)
65-74 7,632 28.7 (27.7-29.8) 10.3 (9.6-11.1) 2.4 (2.0-2.9) 1.0 (0.6-1.6)
75+ 6,384 12.1 (11.3-13.0) 3.8 (3.3-4.3) 1.1 (0.8-1.5) -- --
Oligodendroglioma 0-19 216 96.2 (92.6-98.1) 94.3 (90.0-96.7) 91.1 (86.0-94.4) 89.0 (83.2-92.8)
20-44 1,539 98.6 (97.8-99.1) 96.2 (95.0-97.1) 87.5 (85.5-89.3) 70.2 (66.8-73.3)
45-54 703 94.6 (92.5-96.1) 90.0 (87.3-92.2) 80.5 (76.8-83.7) 64.3 (58.9-69.3)
55-64 377 88.7 (84.8-91.6) 78.3 (73.3-82.4) 68.1 (62.1-73.4) 50.3 (41.9-58.1)
65-74 160 79.6 (72.0-85.3) 72.5 (64.0-79.3) 52.3 (42.4-61.3) 33.5 (21.6-45.8)
75+ 86 61.2 (49.0-71.3) 52.2 (39.4-63.5) 41.9 (27.3-55.7) -- --
Anaplastic oligodendroglioma 0-19 -- -- -- -- -- -- -- -- --
20-44 510 94.1 (91.6-95.9) 85.3 (81.8-88.3) 71.2 (66.6-75.4) 54.2 (48.3-59.8)
45-54 324 88.4 (84.2-91.6) 77.0 (71.7-81.5) 61.2 (54.8-67.0) 44.5 (36.9-51.8)
55-64 268 78.0 (72.3-82.6) 62.5 (56.0-68.3) 46.1 (39.1-52.8) 34.1 (25.9-42.5)
65-74 121 54.3 (44.6-62.9) 34.6 (25.6-43.8) 18.3 (10.7-27.5) -- --
75+ -- -- -- -- -- -- -- -- --
Ependymal tumors 0-19 772 94.7 (92.8-96.1) 87.7 (85.0-89.9) 75.6 (71.9-78.8) 67.0 (62.4-71.1)
20-44 846 97.3 (95.9-98.2) 95.3 (93.5-96.6) 91.6 (89.1-93.5) 89.4 (86.1-91.9)
45-54 507 95.2 (92.8-96.9) 93.0 (90.1-95.0) 89.2 (85.5-92.1) 88.0 (83.7-91.3)
55-64 356 92.6 (89.0-95.0) 88.9 (84.7-92.1) 86.2 (80.9-90.1) 85.1 (76.9-90.6)
65-74 166 89.4 (82.8-93.5) 82.7 (74.9-88.3) 80.5 (71.9-86.8) 73.5 (55.5-85.1)
75+ 86 70.8 (58.5-80.0) 66.6 (53.1-77.0) 53.7 (36.9-67.9) 33.7 (11.5-57.9)
Oligoastrocytic tumors 0-19 116 94.8 (88.6-97.7) 89.3 (81.8-93.8) 83.7 (74.8-89.7) 77.4 (66.6-85.1)
20-44 1,090 96.8 (95.5-97.8) 90.6 (88.6-92.3) 72.8 (69.5-75.7) 54.6 (50.1-58.8)
45-54 411 89.4 (85.8-92.1) 78.8 (74.2-82.7) 66.2 (60.6-71.2) 47.1 (39.0-54.7)
55-64 229 74.1 (67.7-79.4) 51.1 (44.0-57.7) 35.4 (28.0-42.9) 30.5 (21.8-39.7)
65-74 131 67.2 (57.8-74.9) 48.0 (38.2-57.1) 29.2 (19.9-39.1) 15.9 (7.0-28.1)
75+ -- -- -- -- -- -- -- -- --
Glioma malignant, NOS 0-19 1,690 77.5 (75.4-79.4) 66.7 (64.2-68.9) 63.2 (60.7-65.6) 61.6 (58.9-64.1)
20-44 883 88.2 (85.8-90.2) 79.5 (76.5-82.2) 68.3 (64.7-71.7) 54.2 (49.3-58.9)
45-54 452 74.5 (70.1-78.4) 60.4 (55.4-65.0) 49.8 (44.5-54.9) 40.9 (34.9-46.9)
55-64 372 55.4 (50.1-60.5) 42.5 (37.1-47.8) 32.6 (27.1-38.2) 26.9 (20.5-33.6)
65-74 365 38.0 (32.9-43.1) 24.2 (19.7-29.1) 16.5 (12.2-21.3) 13.2 (8.7-18.6)
75+ 700 16.9 (14.0-19.9) 12.9 (10.2-15.8) 9.4 (6.7-12.6) 8.5 (4.7-13.7)
Neuronal and mixed neuronal-glial tumors 0-19 66 93.6 (83.8-97.6) 88.6 (77.4-94.4) 84.9 (72.8-91.9) 84.9 (72.8-91.9)
20-44 145 96.4 (91.3-98.6) 90.7 (84.0-94.7) 78.8 (69.7-85.4) 64.7 (51.6-75.1)
45-54 125 93.7 (87.2-96.9) 89.4 (81.7-94.0) 82.9 (73.6-89.1) 72.2 (56.4-83.1)
55-64 97 90.7 (82.0-95.4) 79.6 (68.5-87.1) 67.1 (54.3-77.1) 51.5 (33.9-66.6)
65-74 57 83.6 (70.0-91.4) 80.9 (65.8-89.9) 77.1 (60.1-87.6) 38.8 (9.8-68.0)
75+ -- -- -- -- -- -- -- -- --
Embryonal tumors 0-19 2,018 80.9 (79.1-82.6) 70.9 (68.8-72.9) 61.8 (59.5-64.1) 55.4 (52.8-58.0)
20-44 552 86.4 (83.1-89.1) 79.2 (75.4-82.6) 66.5 (61.9-70.7) 58.4 (53.1-63.3)
45-54 84 82.7 (72.3-89.5) 68.6 (56.6-78.0) 56.7 (43.4-68.0) 36.6 (20.0-53.4)
55-64 -- -- -- -- -- -- -- -- --
65-74 -- -- -- -- -- -- -- -- --
75+ -- -- -- -- -- -- -- -- --
Meningioma 0-19 -- -- -- -- -- -- -- -- --
20-44 139 95.0 (89.5-97.6) 94.4 (88.7-97.3) 87.0 (79.3-92.0) 77.7 (67.9-84.9)
45-54 181 92.4 (87.2-95.6) 86.1 (79.7-90.6) 77.4 (69.5-83.4) 69.4 (60.0-77.0)
55-64 255 88.3 (83.3-91.8) 81.7 (75.9-86.2) 70.5 (63.4-76.5) 60.2 (51.6-67.8)
65-74 238 80.7 (74.6-85.5) 70.2 (63.1-76.1) 53.7 (45.4-61.4) 47.9 (37.2-57.9)
75+ 282 61.6 (55.0-67.6) 54.8 (47.6-61.5) 47.3 (38.4-55.7) 37.1 (24.9-49.3)
Lymphoma 0-19 66 84.5 (73.1-91.4) 78.0 (65.6-86.4) 72.6 (59.5-82.1) 67.4 (53.0-78.3)
20-44 755 55.7 (52.0-59.2) 49.5 (45.8-53.1) 43.1 (39.3-46.8) 37.8 (33.6-42.0)
45-54 694 61.3 (57.5-64.9) 52.6 (48.6-56.3) 41.2 (37.1-45.2) 31.0 (26.5-35.7)
55-64 951 61.3 (58.1-64.4) 52.5 (49.1-55.8) 38.1 (34.5-41.7) 29.7 (25.6-33.9)
65-74 1,063 49.8 (46.7-52.9) 40.9 (37.7-44.1) 26.9 (23.7-30.2) 16.9 (13.2-21.1)
75+ 920 32.8 (29.6-36.0) 23.2 (20.3-26.3) 15.3 (12.3-18.6) 10.8 (6.7-16.1)
TOTAL: All Malignant Brain and Other Nervous System Tumors e 0-19 10,406 87.1 (86.4-87.7) 79.9 (79.1-80.7) 73.8 (72.9-74.7) 70.2 (69.1-71.2)
20-44 14,250 86.3 (85.7-86.9) 75.6 (74.8-76.3) 61.5 (60.6-62.4) 49.5 (48.4-50.6)
45-54 11,178 68.9 (68.0-69.8) 48.0 (47.0-49.0) 33.5 (32.5-34.5) 26.3 (25.2-27.4)
55-64 13,481 53.5 (52.6-54.4) 31.0 (30.2-31.8) 18.5 (17.7-19.2) 14.1 (13.2-14.9)
65-74 11,598 36.2 (35.3-37.1) 20.2 (19.4-21.0) 11.2 (10.5-11.9) 8.0 (7.2-8.8)
75+ 10,917 17.7 (17.0-18.5) 10.2 (9.6-10.8) 6.3 (5.7-7.0) 4.2 (3.5-5.1)

aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.

bRates are an estimate of the percentage of patients alive at one, two, five, and ten year, respectively. Rates were not presented for categories with 50 or less cases and were suppressed for rates where less than 16 cases were surviving within a category.

cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (2000-2013) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.

dTotal number of case that occurred within the SEER registries between 2000 and 2013.

eIncludes histologies not listed in this table.